(Q36007344)

11 August 2017

1 reference

title

Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? (English)

1 reference

11 August 2017

1 reference

1 reference

Fabien Zoulim

1

1 reference

11 August 2017

language of work or name

1 reference

1 November 2004

1 reference

Antiviral Chemistry & Chemotherapy

11 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

11 August 2017

volume

15

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

299-305

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Lamivudine therapy of WHV-infected woodchucks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Hepatitis B virus biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Hepatocyte turnover during resolution of a transient hepadnaviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500602

10.1177/095632020401500602

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference